Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10525074 Combination therapy for treating cancer

Patent 10525074 was granted and assigned to Epizyme on January, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Scott R. Daigle0

Christine Klaus0

Maria Alejandra Raimondi0

Roy MacFarlane Pollock0

Date of Patent

January 7, 2020

0

Patent Application Number

152480800

Date Filed

August 26, 2016

0

Patent Citations Received

US Patent 10968247 Methods of synthesizing substituted purine compounds

0

US Patent 11753433 Methods of synthesizing substituted purine compounds

US Patent 11285159 Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax

US Patent 11572383 Methods of synthesizing substituted purine compounds

US Patent 11633420 Method of treating leukemia

0

Patent Primary Examiner

Traviss C Mcintosh, III

0

Patent abstract

The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10525074 Combination therapy for treating cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool